- Trials with a EudraCT protocol (708)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
708 result(s) found for: H syndrome.
Displaying page 1 of 36.
EudraCT Number: 2014-004383-37 | Sponsor Protocol Number: SP1004 | Start Date*: 2015-04-08 | |||||||||||
Sponsor Name:UCB BIOSCIENCES, Inc. | |||||||||||||
Full Title: A Multicenter, Open-Label, 2-Group, Dose Escalation Study of Monotherapy Administration of Rotigotine in Pediatric Subjects With Idiopathic Restless Legs Syndrome | |||||||||||||
Medical condition: Restless Legs Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-004928-15 | Sponsor Protocol Number: CA056-015 | Start Date*: 2022-09-28 | |||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||
Full Title: A Phase 2, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Determine the Efficacy and Safety of Luspatercept (BMS-986346/ACE-536) for the Treatment of Anemia in Adults with Alpha... | |||||||||||||
Medical condition: Alpha (α)-thalassemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-005216-27 | Sponsor Protocol Number: 78993095 | Start Date*: 2007-03-26 | |||||||||||
Sponsor Name:HUS, Hospital for Children and Adolescents | |||||||||||||
Full Title: Selkäytimeen annettu entsyymikorvaus mukopolysakkaridoosi I:n selkäytimen puristuman hoidossa. Kansainvälinen monikeskustutkimus. A study of intrathecal enzyme replacement therapy for spinal cord c... | |||||||||||||
Medical condition: Mucopolysaccharidosis I H/S, lysosomal storage disease with clinical manifestations such as progressive joint stiffness, growth retardation, corneal clouding, hepatosplenomegaly, cardiac and respir... | |||||||||||||
|
|||||||||||||
Population Age: | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-000227-25 | Sponsor Protocol Number: CRIT124DDE03 | Start Date*: 2008-10-15 | |||||||||||
Sponsor Name:Dept. Child & Adolescent Psychiatrie | |||||||||||||
Full Title: A single-center, single-blind, randomized, oral dose cross-over study in prepuberal boys with ADHD to investigate efficacy and bioequivalence of 20 mg Ritalin LA® compared to 20 mg Medikinet® retar... | |||||||||||||
Medical condition: Patients having a diagnosis of Attention Deficit Hyperactivity Disorder (ADHD) of any type according to DSM-IV criteria, as established by history, psychiatric examination and a structured diagnost... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-003652-20 | Sponsor Protocol Number: Ptcl-01501 | Start Date*: 2013-12-04 | |||||||||||
Sponsor Name:D-Pharm Ltd. | |||||||||||||
Full Title: Pilot trial of intravenous DP-b99 in the treatment of first-ever episode of non-obstructive acute high-risk pancreatitis | |||||||||||||
Medical condition: Acute pancreatitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) SK (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000635-40 | Sponsor Protocol Number: SP1005 | Start Date*: 2016-03-16 | |||||||||||
Sponsor Name:UCB BIOSCIENCES, Inc. | |||||||||||||
Full Title: AN OPEN-LABEL, LONG-TERM FOLLOW-UP STUDY TO DETERMINE THE SAFETY, TOLERABILITY, AND EFFICACY OF ROTIGOTINE TRANSDERMAL SYSTEM AS MONOTHERAPY IN ADOLESCENTS WITH RESTLESS LEGS SYNDROME | |||||||||||||
Medical condition: Restless Legs Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000802-23 | Sponsor Protocol Number: 11.111A | Start Date*: 2011-07-05 | |||||||||||
Sponsor Name:Javier García Campayo | |||||||||||||
Full Title: Efficacy of memantine in the treatment of fibromyalgia: an open, uncontrolled, exploratory 3-months follow-up study | |||||||||||||
Medical condition: Fibromialgia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003029-83 | Sponsor Protocol Number: OSAS_UCBH | Start Date*: 2020-12-03 | |||||||||||
Sponsor Name:Service de Neurologie, CHU Liège | |||||||||||||
Full Title: Assessment of changes in regional brain synaptic density in patients with Obstructive Sleep Apnea (OSA) measured by positron emission tomography and 18F-UCB-H. | |||||||||||||
Medical condition: Obstructive sleep apnea syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001505-93 | Sponsor Protocol Number: P11-11 | Start Date*: 2013-12-19 | |||||||||||
Sponsor Name:Bioprojet Pharma | |||||||||||||
Full Title: A MULTI-CENTRE, SINGLE DOSE TRIAL TO EVALUATE PHARMACOKINETICS OF PITOLISANT (BF2.649) IN CHILDREN FROM 6 TO LESS THAN 18 YEARS WITH NARCOLEPSY | |||||||||||||
Medical condition: Narcolepsy | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) FR (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002969-35 | Sponsor Protocol Number: P40919/SAFFE2012 | Start Date*: 2013-08-19 | |||||||||||
Sponsor Name:Imperial College | |||||||||||||
Full Title: Slow-wave sleep and daytime functioning in chronic fatigue syndrome: effects of sodium oxybate | |||||||||||||
Medical condition: Chronic fatigue syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004547-36 | Sponsor Protocol Number: CCD-01534CA1-01 | Start Date*: 2017-03-16 | |||||||||||
Sponsor Name:Chiesi Farmaceutici S.p.A. | |||||||||||||
Full Title: A RANDOMIZED, OPEN, MULTINATIONAL, MULTICENTRE, 2-PART STUDY IN SPONTANEOUSLY BREATHING PRETERM NEONATES WITH MILD TO MODERATE RESPIRATORY DISTRESS SYNDROME TO INVESTIGATE THE SAFETY, TOLERABILITY ... | |||||||||||||
Medical condition: Mild to moderate respiratory distress syndrome | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) CZ (Prematurely Ended) GB (Prematurely Ended) AT (Prematurely Ended) FR (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004073-76 | Sponsor Protocol Number: CAAA001A12401 | Start Date*: 2020-10-12 | ||||||||||||||||
Sponsor Name:Advanced Accelerator Applications International SA | ||||||||||||||||||
Full Title: A multicenter, open-label post authorization safety study to evaluate the effect of LysaKare® infusion on serum potassium levels in GEP-NET patients eligible for Lutathera® treatment | ||||||||||||||||||
Medical condition: LysaKare® is indicated for reduction of renal radiation exposure during peptide-receptor radionuclide therapy (PRRT) with lutetium (177 Lu) oxodotreotide in adults. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Completed) IT (Completed) PL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-000564-28 | Sponsor Protocol Number: IIBSP-QTL-2017-96 | Start Date*: 2018-05-23 |
Sponsor Name:Institut de Recerca H. de la Santa Creu i Sant Pau - IIB Sant Pau | ||
Full Title: Genetic characterization of drug-induced Long QT Syndrome | ||
Medical condition: Drug-induced Long QT Syndrome | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-001078-27 | Sponsor Protocol Number: 19999 | Start Date*: 2020-06-16 | |||||||||||
Sponsor Name:Bayer AG | |||||||||||||
Full Title: Safety and efficacy of inhaled pegylated adrenomedullin (PEG-ADM) in patients suffering from Acute Respiratory Distress Syndrome (ARDS): a double-blind, randomized, placebo-controlled, multicenter ... | |||||||||||||
Medical condition: Acute respiratory distress syndrome (ARDS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) CZ (Completed) AT (Prematurely Ended) IT (Prematurely Ended) GR (Prematurely Ended) NL (Prematurely Ended) BE (Completed) DK (Prematurely Ended) IE (Prematurely Ended) FI (Prematurely Ended) HU (Prematurely Ended) SK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002370-12 | Sponsor Protocol Number: IMI2016-2 | Start Date*: 2016-12-29 | ||||||||||||||||
Sponsor Name:Charité Universitätsmedizin Berlin | ||||||||||||||||||
Full Title: PROOF OF CONCEPT STUDY OF HYQVIA IN PATIENTS WITH IMMUNOGLOBULIN DEFICIENCY AND RECURRENT INFECTIONS WITH CHRONIC FATIGUE SYNDROME | ||||||||||||||||||
Medical condition: Immunoglobulin deficiency and recurrent infections with chronic fatigue syndrome | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-005624-26 | Sponsor Protocol Number: 03-CL-1401 | Start Date*: 2016-05-30 | |||||||||||||||||||||
Sponsor Name:Windtree Therapeutics, Inc. (formerly Discovery Laboratories, Inc.) | |||||||||||||||||||||||
Full Title: A Multicenter, Randomized, Open-Label, Controlled Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Preterm Neonates 26 to 28 Weeks PMA. | |||||||||||||||||||||||
Medical condition: Respiratory Distress Syndrome (RDS) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: PL (Prematurely Ended) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-006953-41 | Sponsor Protocol Number: C08-002B | Start Date*: 2009-08-19 | |||||||||||
Sponsor Name:ALEXION PHARMACEUTICALS, INC. | |||||||||||||
Full Title: AN OPEN-LABEL, MULTI-CENTER CONTROLLED CLINICAL TRIAL OF ECULIZUMAB IN ADOLESCENT PATIENTS WITH PLASMA THERAPY-RESISTANT ATYPICAL HEMOLYTIC-UREMIC SYNDROME (AHUS) | |||||||||||||
Medical condition: Adolescent patients (from 12 and up to 18 years of age weighing ≥ 40 kg) with plasma therapyresistant Atypical Hemolytic-Uremic Syndrome (aHUS). | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) NL (Completed) SE (Completed) AT (Completed) GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-005182-37 | Sponsor Protocol Number: OT-0401 | Start Date*: 2005-07-25 | |||||||||||
Sponsor Name:Curatis Pharma GmbH | |||||||||||||
Full Title: A double-blind, randomized, placebo-controlled, multicenter phase III study of intravenous terlipressin in patients with hepatorenal syndrome type 1 | |||||||||||||
Medical condition: Hepatorenal Syndrome Type 1 | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-006952-23 | Sponsor Protocol Number: C08-002A | Start Date*: 2009-08-19 | |||||||||||
Sponsor Name:ALEXION PHARMACEUTICALS, INC. | |||||||||||||
Full Title: AN OPEN-LABEL, MULTI-CENTER CONTROLLED CLINICAL TRIAL OF ECULIZUMAB IN ADULT PATIENTS WITH PLASMA THERAPY-RESISTANT ATYPICAL HEMOLYTIC-UREMIC SYNDROME (AHUS) | |||||||||||||
Medical condition: Adult patients with plasma therapy-resistant Atypical Hemolytic-Uremic Syndrome (aHUS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) NL (Completed) SE (Completed) AT (Completed) FR (Completed) ES (Prematurely Ended) GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-006954-17 | Sponsor Protocol Number: C08-003A | Start Date*: 2009-06-18 | |||||||||||
Sponsor Name:ALEXION PHARMACEUTICALS, INC. | |||||||||||||
Full Title: AN OPEN-LABEL, MULTI-CENTER CONTROLLED CLINICAL TRIAL OF ECULIZUMAB IN ADULT PATIENTS WITH PLASMA THERAPY-SENSITIVE ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS) | |||||||||||||
Medical condition: Adult patients with plasma therapy-sensitive Atypical Hemolytic-Uremic Syndrome (aHUS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) NL (Completed) SE (Completed) AT (Completed) FR (Completed) ES (Prematurely Ended) GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
